Mobbing as a problem in management ethics

A positive company image and its good reputation are usually results of ethical and honest behaviour towards employees and may improve competitiveness, increase profits, customer satisfaction, and create new job jobs. However, it often occurs in dynamically developing firms where ethical norms are not kept and this process can be seen in the lack of equal chances to get a job – people without connections remain without work. According to research, mobbing is a very serious problem. Psychological terror or mobbing in work life involves hostile and unethical communication that is conducted in a systematic manner by one or more individuals, mainly toward one individual, who, due to mobbing, is pushed into a helpless and defenceless position and held there by means of continuing mobbing activities. These actions occur on a very frequent basis (statistical definition: at least once a week) and over a long period (statistical definition: at least six months’ duration). Because of the high frequency and long duration of hostile behaviour, this maltreatment results in considerable mental, psychosomatic, and social misery.Publication of English-language versions of the volumes of the "Annales. Ethics in Economic Life" financed through contract no. 501/1/P-DUN/2017 from the funds of the Ministry of Science and Higher Education devoted to the promotion of scholarship

Different technical possibilities of post- -therapeutic tandem 90Y/ /177Lu-DOTATATE imaging

BACKGROUND: Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms derived from endocrine stem cells.These tumors are characterized by overexpression of somatostatinreceptors (SSTR), which is utilized for imaging using SSTR analogs. Peptide receptor radionuclide therapy (PRRT) somatostatinanalogs labeled with 90Y and 177Lu in neuroendocrine tumors (NETs) results in symptomatic improvement, prolonged survival,and enhanced quality of life. The post-therapeutic imaging leadsto possibility of biodistribution of therapy. The aim of our study was to describe different possibilities of post-therapeutic imaging in patients underwent tandem therapy90Y/177Lu-DOTATATE with preliminary results of 90Y PET imaging.MATERIAL AND METHODS: Thirty patients (11 men, 19 women; the mean age 55 ± 10.9 y) with histological confirmationof metastatic neuroendocrine tumors (G1 and G2) were treated with tandem therapy 90Y/177Lu-DOTATATE. WHBA scan and SPECT acquisition of the abdomen were performed 24 hours post therapy injection, on the dual-headVaricam camera (ELSCINT) using 177Lu photopeak and 90Y bremsstrahlung. PET imaging of 90Y component was done on Siemens Biograph Truepoint PET/CT (window 511 keV ± 15%) 4 hours after 90Y/177Lu-DOTATATE. Additionally phantom studies were performer to analyze the spatial resolution of different protocols.RESULTS: Out of all the patients, median OS was 49.8 months and median EFS time 24.3 months. Spatial resolution achieved for 90Y, 177 Lu and PET imaging of 90Y componentmeasured using the phantom of the torso filled up with water was 20 mm, 8 mm and 4–5 mm FWHM, respectively. Spatial resolution in human body in our study was about 30 mm for 90Y, 15 mm for 177Lu and 25–30 mm for PET imaging of 90Y component.CONCLUSIONS: The theoretically best spatial resolution offers PET scanner, however it is important to keep in mind that90Y-imaging PET is not used for diagnosis purposes (small activities)but rather to present new possibility of post-therapeutic imaging (substantially higher activities). For post-therapeutic imaging after intravenous radiopharmaceutical administration the best spatial resolution offers standard scintigraphic camera for 90Y/177Lu DOTATATE imaging, withusing 177Lu photopeaks. The worst spatial resolution offers standard scintigraphic camera for 90Y/177Lu DOTATATE imaging, with using 90Y bremsstrahlunggammas

Home-based treatment with subcutaneous trastuzumab: safe and acceptable not only during a pandemic — final analysis of the RWD project ‘FlexCare’

Introduction. Trastuzumab shows similar efficacy and safety profile regardless of IV or SC administration. Subcutaneous administration enables reduction of treatment costs and time as well as equipment savings and is more convenient for both patients and healthcare providers. In Poland, home-based programs of treatment with biological drugs are already implemented; however, to date they do not include trastuzumab in BC patients. The project aimed to evaluate the organizational and therapeutic procedures related to home-based treatment with subcutaneous trastuzumab and satisfaction of patients and healthcare providers based on RWE. Material and methods. Early HER2(+) BC patients treated with trastuzumab were enrolled in the study. Monitoring and duration of treatment were consistent with the summary of product characteristics (SmPC) and reimbursement rules. The first 3–6 doses of trastuzumab were administered at the cancer center, followed by home doses. Medical visits took place every 3 months. The data were analyzed using descriptive statistics. A positive opinion of the Bioethics Committee was obtained. Results. Twenty patients participated in the project. The median age was 59 years (36–72 years). The average distance from the place of residence to the hospital was 24 km (2–65 km). We administered 232 doses, with an average of 11.6 doses per patient (range 6–14). The tolerance of trastuzumab was good and consistent with the SmPC. The average duration of a nurse’s stay at home was 60 minutes. Almost all patients (19/20) appreciated the possibility of saving time and continuing their professional work as well as avoiding crowds and the risk of infection in the hospital. Two patients felt that nurse visits violated their privacy. No logistical or technical problems were observed. Conclusions. Home-based treatment with subcutaneously administered trastuzumab is safe and easy to organize, positively perceived by both patients and nurses. It can be particularly important for disabled patients who have difficulty reaching the hospital, as well as for professionally active patients

Childhood thyroid carcinoma – an experience of one center

Papillary thyroid carcinoma (PTC) is the most common histological form of thyroid cancer in children and is characterized by a very good prognosis. However lymph node and lung metastases in PTC occur more frequently in pediatric patients than in adults. Ultrasound together with fine needle aspiration biopsy (FNAB) are the gold standard in the diagnosis of thyroid nodules in children. A new valuable diagnostic method became also elastography. The gold treatment standard remains thyroidectomy. In young patients with lymph node and/or distant metastases, there is abundant evidence to show that disease-free survival is improved by radioactive iodine (RAI) therapy. We present three patients diagnosed with PTC in Department of Paediatrics, Endocrinology, Diabetology with Cardiology Division, Medical University of Bialystok, Poland treated with the cooperation of the Department of Nuclear Medicine and Endocrine Oncology at M. Skłodowska-Curie National Research Institute in Gliwice, Poland

Primary care practitioners’ diagnostic action when the patient may have cancer : an exploratory vignette study in 20 European countries

Availability of data To avoid the risk of identification of individual participants, the datasets generated and analysed during the current study are not publicly available. However, they are available (with any possible identifying information redacted) from the corresponding author on reasonable request. Funding This study received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. ALN’s time is supported by the National Institute for Health Research (NIHR) Imperial Patient Safety Translation Research Centre, with her infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). Acknowledgements We would like to thank all the PCPs who piloted the questionnaire and those who completed the survey. We would also like to thank the European GP Research Network for its support. We are grateful to Prof. Barbara Silverman and Prof. Lital Keinan for the data on cancer survival rates in Israel, and to Dr Yochai Schonmann for his work on those data. Two of the vignettes were used by kind permission of the ICBP; we also thank Dr Peter Murchie and Dr Rhona Auckland, who generously provided the other two vignettes. Prof. Antonius Schneider kindly organised the Technical University of Munich’s data collection.Peer reviewedPublisher PD

Identifying important health system factors that influence primary care practitioners' referrals for cancer suspicion : a European cross-sectional survey

ALN is supported by the National Institute for Health Research (NIHR) Imperial Patient Safety Translation Research Centre, with infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/bmjopen-2018-022904).Peer reviewedPublisher PD

Why do European primary care physicians sometimes not think of, or act on, a possible cancer diagnosis? : A qualitative study

Funding The Swedish application for ethical approval was funded by the Jämtland Cancer and Nursing Foundation. The study had no other external fundingPeer reviewedPostprin

Nauka prawa finansowego po I dekadzie XXI wieku

Księga pamiątkowa dedykowana profesorowi Apoloniuszowi Kosteckiem